STOCK TITAN

[Form 4] Immunic, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Colony Bankcorp Inc. (CBAN) Form 4 highlights: Director Matthew D. Reed reported the grant of 969 restricted shares on 07/15/2025. Following the award, he now directly owns 16,736 common shares, up roughly 6% from the pre-grant level (~15,767). In addition, Reed holds 448 shares indirectly through an IRA for Kennedy K. Reed. No derivative securities, sales, or open-market purchases were disclosed.

The filing reflects a routine equity-based compensation grant and modestly increases insider ownership, which can align director incentives with shareholder interests. However, because the shares were granted (not purchased with personal funds), the transaction’s immediate signaling value is limited. No other material events, financial metrics, or changes to ownership structure were reported.

Colony Bankcorp Inc. (CBAN) Form 4 in evidenza: Il direttore Matthew D. Reed ha segnalato la concessione di 969 azioni vincolate il 15/07/2025. Dopo questa assegnazione, possiede ora direttamente 16.736 azioni ordinarie, con un aumento di circa il 6% rispetto al livello precedente (~15.767). Inoltre, Reed detiene 448 azioni indirettamente tramite un IRA intestato a Kennedy K. Reed. Non sono state dichiarate operazioni su strumenti derivati, vendite o acquisti sul mercato aperto.

La comunicazione riflette una consueta assegnazione di compensi basati su azioni e incrementa modestamente la proprietà interna, un elemento che può allineare gli interessi del direttore con quelli degli azionisti. Tuttavia, poiché le azioni sono state concesse (non acquistate con fondi personali), il valore informativo immediato dell’operazione è limitato. Non sono stati riportati altri eventi rilevanti, indicatori finanziari o variazioni nella struttura proprietaria.

Aspectos destacados del Formulario 4 de Colony Bankcorp Inc. (CBAN): El director Matthew D. Reed reportó la concesión de 969 acciones restringidas el 15/07/2025. Tras esta adjudicación, ahora posee directamente 16,736 acciones ordinarias, un aumento aproximado del 6% respecto al nivel previo (~15,767). Además, Reed posee 448 acciones indirectamente a través de una IRA para Kennedy K. Reed. No se divulgaron valores derivados, ventas ni compras en mercado abierto.

La presentación refleja una concesión rutinaria de compensación basada en acciones y aumenta modestamente la propiedad interna, lo que puede alinear los incentivos del director con los intereses de los accionistas. Sin embargo, dado que las acciones fueron concedidas (no compradas con fondos personales), el valor informativo inmediato de la transacción es limitado. No se reportaron otros eventos materiales, métricas financieras o cambios en la estructura de propiedad.

Colony Bankcorp Inc. (CBAN) Form 4 주요 내용: 이사 Matthew D. Reed가 2025년 7월 15일에 969주의 제한 주식 부여를 보고했습니다. 이번 부여 이후 그는 현재 직접 16,736주의 보통주를 보유하고 있으며, 이는 부여 전 약 6%(약 15,767주) 증가한 수치입니다. 또한 Reed는 Kennedy K. Reed 명의의 IRA를 통해 간접적으로 448주를 보유하고 있습니다. 파생 증권, 매도 또는 공개 시장 매수는 보고되지 않았습니다.

이번 보고는 일상적인 주식 기반 보상 부여를 반영하며 내부자 소유를 소폭 증가시켜 이사의 인센티브를 주주 이익과 일치시킬 수 있습니다. 다만, 주식이 부여된 것이지 개인 자금으로 구매한 것이 아니기 때문에 거래의 즉각적인 신호 가치는 제한적입니다. 다른 중요한 사건, 재무 지표 또는 소유 구조 변화는 보고되지 않았습니다.

Points clés du Formulaire 4 de Colony Bankcorp Inc. (CBAN) : Le directeur Matthew D. Reed a déclaré l’octroi de 969 actions restreintes le 15/07/2025. Suite à cette attribution, il détient désormais directement 16 736 actions ordinaires, soit une augmentation d’environ 6 % par rapport au niveau avant attribution (~15 767). De plus, Reed détient 448 actions indirectement via un IRA pour Kennedy K. Reed. Aucune opération sur titres dérivés, vente ou achat sur le marché ouvert n’a été divulguée.

Le dépôt reflète une attribution de rémunération en actions de routine et augmente modestement la détention d’initiés, ce qui peut aligner les incitations du directeur avec les intérêts des actionnaires. Toutefois, comme les actions ont été attribuées (et non achetées avec des fonds personnels), la valeur informative immédiate de la transaction est limitée. Aucun autre événement important, indicateur financier ou changement dans la structure de propriété n’a été rapporté.

Colony Bankcorp Inc. (CBAN) Form 4 Highlights: Direktor Matthew D. Reed meldete am 15.07.2025 die Gewährung von 969 eingeschränkten Aktien. Nach der Zuteilung besitzt er nun direkt 16.736 Stammaktien, was einem Anstieg von etwa 6 % gegenüber dem Vorher-Niveau (~15.767) entspricht. Zusätzlich hält Reed 448 Aktien indirekt über ein IRA für Kennedy K. Reed. Es wurden keine Derivate, Verkäufe oder Käufe am offenen Markt gemeldet.

Die Meldung spiegelt eine routinemäßige aktienbasierte Vergütung wider und erhöht den Insiderbesitz leicht, was die Anreize des Direktors mit den Interessen der Aktionäre in Einklang bringen kann. Da die Aktien jedoch gewährt wurden (nicht mit privaten Mitteln gekauft), ist der unmittelbare Signalwert der Transaktion begrenzt. Weitere wesentliche Ereignisse, Finanzkennzahlen oder Änderungen in der Eigentümerstruktur wurden nicht gemeldet.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine restricted-stock grant lifts director’s stake 6%; alignment positive but signal limited versus open-market buy.

Restricted stock awards are standard board compensation. Reed’s direct ownership rises to 16,736 shares, keeping directors’ interests aligned with investors. Because no cash outlay was made, market shouldn’t infer the same confidence as an outright purchase. No red flags—no sales, pledges, or derivative positions—so governance risk remains low. Impact: neutral-positive.

TL;DR: Small, non-cash insider acquisition; negligible valuation impact.

The 969-share grant equates to <1% of CBAN’s ~9.0 m shares outstanding, therefore immaterial to float or supply/demand. Because the stock was awarded, not bought, it doesn’t convey incremental bullish sentiment. I view the event as routine and non-impactful for portfolio positioning.

Colony Bankcorp Inc. (CBAN) Form 4 in evidenza: Il direttore Matthew D. Reed ha segnalato la concessione di 969 azioni vincolate il 15/07/2025. Dopo questa assegnazione, possiede ora direttamente 16.736 azioni ordinarie, con un aumento di circa il 6% rispetto al livello precedente (~15.767). Inoltre, Reed detiene 448 azioni indirettamente tramite un IRA intestato a Kennedy K. Reed. Non sono state dichiarate operazioni su strumenti derivati, vendite o acquisti sul mercato aperto.

La comunicazione riflette una consueta assegnazione di compensi basati su azioni e incrementa modestamente la proprietà interna, un elemento che può allineare gli interessi del direttore con quelli degli azionisti. Tuttavia, poiché le azioni sono state concesse (non acquistate con fondi personali), il valore informativo immediato dell’operazione è limitato. Non sono stati riportati altri eventi rilevanti, indicatori finanziari o variazioni nella struttura proprietaria.

Aspectos destacados del Formulario 4 de Colony Bankcorp Inc. (CBAN): El director Matthew D. Reed reportó la concesión de 969 acciones restringidas el 15/07/2025. Tras esta adjudicación, ahora posee directamente 16,736 acciones ordinarias, un aumento aproximado del 6% respecto al nivel previo (~15,767). Además, Reed posee 448 acciones indirectamente a través de una IRA para Kennedy K. Reed. No se divulgaron valores derivados, ventas ni compras en mercado abierto.

La presentación refleja una concesión rutinaria de compensación basada en acciones y aumenta modestamente la propiedad interna, lo que puede alinear los incentivos del director con los intereses de los accionistas. Sin embargo, dado que las acciones fueron concedidas (no compradas con fondos personales), el valor informativo inmediato de la transacción es limitado. No se reportaron otros eventos materiales, métricas financieras o cambios en la estructura de propiedad.

Colony Bankcorp Inc. (CBAN) Form 4 주요 내용: 이사 Matthew D. Reed가 2025년 7월 15일에 969주의 제한 주식 부여를 보고했습니다. 이번 부여 이후 그는 현재 직접 16,736주의 보통주를 보유하고 있으며, 이는 부여 전 약 6%(약 15,767주) 증가한 수치입니다. 또한 Reed는 Kennedy K. Reed 명의의 IRA를 통해 간접적으로 448주를 보유하고 있습니다. 파생 증권, 매도 또는 공개 시장 매수는 보고되지 않았습니다.

이번 보고는 일상적인 주식 기반 보상 부여를 반영하며 내부자 소유를 소폭 증가시켜 이사의 인센티브를 주주 이익과 일치시킬 수 있습니다. 다만, 주식이 부여된 것이지 개인 자금으로 구매한 것이 아니기 때문에 거래의 즉각적인 신호 가치는 제한적입니다. 다른 중요한 사건, 재무 지표 또는 소유 구조 변화는 보고되지 않았습니다.

Points clés du Formulaire 4 de Colony Bankcorp Inc. (CBAN) : Le directeur Matthew D. Reed a déclaré l’octroi de 969 actions restreintes le 15/07/2025. Suite à cette attribution, il détient désormais directement 16 736 actions ordinaires, soit une augmentation d’environ 6 % par rapport au niveau avant attribution (~15 767). De plus, Reed détient 448 actions indirectement via un IRA pour Kennedy K. Reed. Aucune opération sur titres dérivés, vente ou achat sur le marché ouvert n’a été divulguée.

Le dépôt reflète une attribution de rémunération en actions de routine et augmente modestement la détention d’initiés, ce qui peut aligner les incitations du directeur avec les intérêts des actionnaires. Toutefois, comme les actions ont été attribuées (et non achetées avec des fonds personnels), la valeur informative immédiate de la transaction est limitée. Aucun autre événement important, indicateur financier ou changement dans la structure de propriété n’a été rapporté.

Colony Bankcorp Inc. (CBAN) Form 4 Highlights: Direktor Matthew D. Reed meldete am 15.07.2025 die Gewährung von 969 eingeschränkten Aktien. Nach der Zuteilung besitzt er nun direkt 16.736 Stammaktien, was einem Anstieg von etwa 6 % gegenüber dem Vorher-Niveau (~15.767) entspricht. Zusätzlich hält Reed 448 Aktien indirekt über ein IRA für Kennedy K. Reed. Es wurden keine Derivate, Verkäufe oder Käufe am offenen Markt gemeldet.

Die Meldung spiegelt eine routinemäßige aktienbasierte Vergütung wider und erhöht den Insiderbesitz leicht, was die Anreize des Direktors mit den Interessen der Aktionäre in Einklang bringen kann. Da die Aktien jedoch gewährt wurden (nicht mit privaten Mitteln gekauft), ist der unmittelbare Signalwert der Transaktion begrenzt. Weitere wesentliche Ereignisse, Finanzkennzahlen oder Änderungen in der Eigentümerstruktur wurden nicht gemeldet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Tardio Jason

(Last) (First) (Middle)
1200 AVENUE OF THE AMERICAS, SUITE 200

(Street)
NEW YORK NY 10036

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
IMMUNIC, INC. [ IMUX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
President and COO
3. Date of Earliest Transaction (Month/Day/Year)
07/16/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Appreciation Right $0.77 07/16/2025 A 330,000 08/01/2026 07/16/2035 Common Stock(1) 330,000 $0.00 330,000 D
Stock Appreciation Right $0.77 07/16/2025 A 660,000 08/01/2026(2) 07/16/2035 Common Stock(1) 660,000 $0.00 660,000 D
Stock Appreciation Right $0.77 07/16/2025 A 660,000 08/01/2026(3) 07/16/2035 Common Stock(1) 660,000 $0.00 660,000 D
Stock Appreciation Right $0.77 07/16/2025 A 330,000 08/01/2026(4) 07/16/2035 Common Stock(1) 330,000 $0.00 330,000 D
Stock Appreciation Right $0.77 07/16/2025 A 330,000 08/01/2026(5) 07/16/2035 Common Stock(1) 330,000 $0.00 330,000 D
Explanation of Responses:
1. The Stock Appreciation Rights ("SARs") could be settled for cash, but it is the intention of the Issuer that these SARs will be settled for shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") provided the Issuer obtains stockholder approval to amend the Issuer's 2019 Omnibus Equity Incentive Plan, as amended, to provide for a sufficient number of shares of Common Stock to support the settlement of the SARs in shares of Common Stock.
2. Exercisable beginning August 1, 2026, subject to the exercise of the Issuer's series A purchase warrants by the holders thereof.
3. Exercisable beginning August 1, 2026, subject to the exercise of the Issuer's series B purchase warrants by the holders thereof.
4. Exercisable beginning August 1, 2026, subject to the Issuer's issuance of Common Stock or pre-funded warrants to subscribers in connection with the second tranche of the Issuer's January 4, 2024 private placement (the "January 2024 Offering").
5. Exercisable beginning August 1, 2026, subject to the Issuer's issuance of Common Stock or pre-funded warrants to subscribers in connection with the third tranche of the January 2024 Offering.
/s/ Jason Tardio 07/18/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many CBAN shares did Director Matthew D. Reed acquire?

He received 969 restricted shares on 07/15/2025.

What is Reed’s total direct ownership after the transaction?

He now directly holds 16,736 CBAN common shares.

Were any CBAN shares sold in this Form 4?

No. The filing only reports an acquisition; there were no dispositions.

Does the filing include derivative securities or options?

No derivative securities were reported; the table for derivatives is blank.

Is the acquisition an open-market purchase?

No, it is a restricted stock award grant, part of board compensation.
Immunic Inc

NASDAQ:IMUX

IMUX Rankings

IMUX Latest News

IMUX Latest SEC Filings

IMUX Stock Data

80.49M
94.52M
1.04%
59.43%
2.66%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW YORK